Generation and characterization of Tmeff2 mutant mice

Biochemical and Biophysical Research Communications

Volumn 425, Issue 2, 2012, Pages 189-194

  Chen, Tian Rui ^a,b   Wang, Ping ^a   Carroll, Liberty K ^a   Zhang, Ying jiu ^b   Han, Bao Xia ^a   Wang, Fan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

Axon innervation; Central nervous system; Growth retardation; Mutant mouse; Peripheral nervous system; Tmeff2

Indexed keywords

ALKALINE PHOSPHATASE; MEMBRANE PROTEIN; TMEFF2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CELL DIFFERENTIATION; ENZYME ACTIVITY; EXON; FIBROBLAST; GROWTH RETARDATION; HOMOZYGOSITY; INTESTINE INNERVATION; MOUSE; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN NERVE; SPINAL CORD; WHITE ADIPOSE TISSUE;

ADIPOGENESIS; ADIPOSE TISSUE, WHITE; ANIMALS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; NERVOUS SYSTEM; NEUROGENESIS; NEURONS;

MUS;

EID: 84865366657     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.064     Document Type: Article

References (35)

1. Uchida T., Wada K., Akamatsu T., Yonezawa M., Noguchi H., Mizoguchi A., Kasuga M., Sakamoto C. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. Biochem. Biophys. Res. Commun. 1999, 266:593-602.
2. Liang G., Robertson K.D., Talmadge C., Sumegi J., Jones P.A. The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells. Cancer Res. 2000, 60:4907-4912.
3. Horie M., Mitsumoto Y., Kyushiki H., Kanemoto N., Watanabe A., Taniguchi Y., Nishino N., Okamoto T., Kondo M., Mori T., Noguchi K., Nakamura Y., Takahashi E., Tanigami A. Identification and characterization of TMEFF2, a novel survival factor for hippocampal and mesencephalic neurons. Genomics 2000, 67:146-152.
4. Young J., Biden K.G., Simms L.A., Huggard P., Karamatic R., Eyre H.J., Sutherland G.R., Herath N., Barker M., Anderson G.J., Fitzpatrick D.R., Ramm G.A., Jass J.R., Leggett B.A. HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers. Proc. Nat. Acad. Sci. U.S.A. 2001, 98:265-270.
5. Glynne-Jones E., Harper M.E., Seery L.T., James R., Anglin I., Morgan H.E., Taylor K.M., Gee J.M., Nicholson R.I. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int. J. Cancer 2001, 94:178-184.
6. Ali N., Knauper V. Phorbol ester-induced shedding of the prostate cancer marker transmembrane protein with epidermal growth factor and two follistatin motifs 2 is mediated by the disintegrin and metalloproteinase-17. J. Biol. Chem. 2007, 282:37378-37388.
7. Afar D.E., Bhaskar V., Ibsen E., Breinberg D., Henshall S.M., Kench J.G., Drobnjak M., Powers R., Wong M., Evangelista F., O'Hara C., Powers D., DuBridge R.B., Caras I., Winter R., Anderson T., Solvason N., Stricker P.D., Cordon-Cardo C., Scher H.I., Grygiel J.J., Sutherland R.L., Murray R., Ramakrishnan V., Law D.A. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol. Cancer Ther. 2004, 3:921-932.
8. Mohler J.L., Morris T.L., Ford O.H., Alvey R.F., Sakamoto C., Gregory C.W. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate 2002, 51:247-255.
9. Gery S., Sawyers C.L., Agus D.B., Said J.W., Koeffler H.P. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 2002, 21:4739-4746.
10. N.J. Belshaw, G.O. Elliott, E.A. Williams, D.M. Bradburn, S.J. Mills, J.C. Mathers, I.T. Johnson, Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 13 (2004) 1495-1501.
11. Geddert H., Kiel S., Iskender E., Florl A.R., Krieg T., Vossen S., Gabbert H.E., Sarbia M. Correlation of hMLH1 and HPP1 hypermethylation in gastric, but not in esophageal and cardiac adenocarcinoma. Int. J. Cancer 2004, 110:208-211.
12. Sato F., Shibata D., Harpaz N., Xu Y., Yin J., Mori Y., Wang S., Olaru A., Deacu E., Selaru F.M., Kimos M.C., Hytiroglou P., Young J., Leggett B., Gazdar A.F., Toyooka S., Abraham J.M., Meltzer S.J. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res. 2002, 62:6820-6822.
13. Shibata D.M., Sato F., Mori Y., Perry K., Yin J., Wang S., Xu Y., Olaru A., Selaru F., Spring K., Young J., Abraham J.M., Meltzer S.J. Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas. Cancer Res. 2002, 62:5637-5640.
14. Suzuki M., Shigematsu H., Shames D.S., Sunaga N., Takahashi T., Shivapurkar N., Iizasa T., Frenkel E.P., Minna J.D., Fujisawa T., Gazdar A.F. DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br. J. Cancer 2005, 93:1029-1037.
15. Suzuki M., Toyooka S., Shivapurkar N., Shigematsu H., Miyajima K., Takahashi T., Stastny V., Zern A.L., Fujisawa T., Pass H.I., Carbone M., Gazdar A.F. Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene 2005, 24:1302-1308.
16. Takahashi T., Shivapurkar N., Riquelme E., Shigematsu H., Reddy J., Suzuki M., Miyajima K., Zhou X., Bekele B.N., Gazdar A.F., Wistuba II Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin. Cancer Res. 2004, 10:6126-6133.
17. Wynter C.V., Walsh M.D., Higuchi T., Leggett B.A., Young J., Jass J.R. Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut 2004, 53:573-580.
18. Chen X., Overcash R., Green T., Hoffman D., Asch A.S., Ruiz-Echevarria M.J. The tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels. J. Biol. Chem. 2011, 286:16091-16100.
19. Hasegawa H., Abbott S., Han B.X., Qi Y., Wang F. Analyzing somatosensory axon projections with the sensory neuron-specific advillin gene. J. Neurosci. 2007, 27:14404-14414.
20. Lawrence J.T., Birnbaum M.J. ADP-ribosylation factor 6 delineates separate pathways used by endothelin 1 and insulin for stimulating glucose uptake in 3T3-L1 adipocytes. Mol. Cell. Biol. 2001, 21:5276-5285.
21. Leighton P.A., Mitchell K.J., Goodrich L.V., Lu X., Pinson K., Scherz P., Skarnes W.C., Tessier-Lavigne M. Defining brain wiring patterns and mechanisms through gene trapping in mice. Nature 2001, 410:174-179.
22. Siegel D.A., Davies P., Dobrenis K., Huang M. Tomoregulin-2 is found extensively in plaques in Alzheimer's disease brain. J. Neurochem. 2006, 98:34-44.
23. Heanue T.A., Pachnis V. Expression profiling the developing mammalian enteric nervous system identifies marker and candidate Hirschsprung disease genes. Proc. Nat. Acad. Sci. U.S.A. 2006, 103:6919-6924.
24. Jijiwa M., Fukuda T., Kawai K., Nakamura A., Kurokawa K., Murakumo Y., Ichihara M., Takahashi M. A targeting mutation of tyrosine, 1062 in ret causes a marked decrease of enteric neurons and renal hypoplasia. Mol. Cell. Biol. 2004, 24:8026-8036.
25. de Graaff E., Srinivas S., Kilkenny C., D'Agati V., Mankoo B.S., Costantini F., Pachnis V. Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev. 2001, 15:2433-2444.
26. Taraviras S., Marcos-Gutierrez C.V., Durbec P., Jani H., Grigoriou M., Sukumaran M., Wang L.C., Hynes M., Raisman G., Pachnis V. Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system. Dev. 1999, 126:2785-2797.
27. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 2008, 77:289-312.
28. Tsai Y.S., Maeda N. PPARgamma: a critical determinant of body fat distribution in humans and mice. Trends Cardiovasc. Med. 2005, 15:81-85.
29. Bluher S., Kratzsch J., Kiess W. Insulin-like growth factor I, growth hormone and insulin in white adipose tissue, best practice & research. Clinical Endocrinology & Metabolism 2005, 19:577-587.
30. Rosen E.D., MacDougald O.A. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 2006, 7:885-896.
31. Lin K., Taylor J.R., Wu T.D., Gutierrez J., Elliott J.M., Vernes J.M., Koeppen H., Phillips H.S., de Sauvage F.J., Meng Y.G. TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. PLoS ONE 2011, 6:e18608.
32. Ng F., Boucher S., Koh S., Sastry K.S., Chase L., Lakshmipathy U., Choong C., Yang Z., Vemuri M.C., Rao M.S., Tanavde V. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008, 112:295-307.
33. Koellensperger E., von Heimburg D., Markowicz M., Pallua N. Human serum from platelet-poor plasma for the culture of primary human preadipocytes. Stem cells 2006, 24:1218-1225.
34. Artemenko Y., Gagnon A., Aubin D., Sorisky A. Anti-adipogenic effect of PDGF is reversed by PKC inhibition. J. Cell. Physiol. 2005, 204:646-653.
35. Gagnon A., Landry A., Sorisky A. IKKbeta and the anti-adipogenic effect of platelet-derived growth factor in human abdominal subcutaneous preadipocytes. J. Endocrinol. 2009, 201:75-80.